EASL 2014: Hepatitis C players seek the spotlight
This article was originally published in Scrip
Executive Summary
The new Gilead Sciences blockbuster hepatitis C drug Sovaldi may be the star of the show at the 49th Annual Meeting of the European Association of the Study of the Liver (EASL) from 9 to 13 April in London, but AbbVie, Merck & Co and others will snag their own share of the spotlight.